Results 251 to 258 of about 33,525 (258)

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

Lancet, The, 2018
Kenneth B Gordon, Bruce E Strober, Mark G Lebwohl   +2 more
exaly  

From Vulnerable Plaque to Vulnerable Patient

Circulation, 2003
Peter Libby, Erling Falk, Christodoulos Stefanadis   +2 more
exaly  

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

Lancet, The, 2017
Kristian Reich, Ka Papp, Andrew Blauvelt
exaly  

Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability

Nature Communications, 2016
Solene Evrard, Gaurav Pandey, K-Raman Purushothaman   +2 more
exaly  

Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice

Science Translational Medicine, 2017
Qiaoqiao Shi, Saba Chowdhury, Rong
exaly  

Acute coronary syndromes without coronary plaque rupture

Nature Reviews Cardiology, 2016
Mandeep Singh, Renu Virmani, Jeffrey W Olin   +2 more
exaly  

Activation of β2-adrenergic receptor stimulates γ-secretase activity and accelerates amyloid plaque formation

Nature Medicine, 2006
exaly  

Atherosclerotic plaque stabilization and regression: a review of clinical evidence

Nature Reviews Cardiology
Ashish Sarraju, Steven Nissen
exaly